MedWatch

Biotech award-winner in search of new capital

‘You have to give before you can get’ seems to be a rule of business for Immudex – a biotech company which constantly tweaks its development-costs to ensure its continued survival.

Foto: Jyllands-Posten

The biotech company Immudex, which - among other things - works on a more reliable borrelia-test than the one currently on the market, is already attempting to secure fresh capital to launch new development projects. But the apparent strategy of the company is still to ensure its continued operation and not to bet everything on development projects – and investors like this approach, says company founder and CEO Henrik Pedersen.

“We see a steady increase in earnings in our company, and if – against all expectations – none of our development projects pan out, the company will still be profitable. So even in the worst case scenario the company will still be around in 10 years time, and we can see that investors light up, when we tell that story,” Henrik Pedersen points out.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier